Outcome-Adaptive Randomization: Is It Useful? von KORN, Edward L, FREIDLIN, Boris

Volltext

Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies von KORN, Edward L, FREIDLIN, Boris, ABRAMS, Jeffrey S

Volltext

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials von KORN, Edward L, LIU, Ping-Yu, PARULEKAR, Wendy, MARKOVIC, Svetomir N, SAXMAN, Scott, KIRKWOOD, John M, LEE, Sandra J, CHAPMAN, Judith-Anne W, NIEDZWIECKI, Donna, SUMAN, Vera J, MOON, James, SONDAK, Vernon K, ATKINS, Michael B, EISENHAUER, Elizabeth A

Volltext

Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis? von Freidlin, Boris, Korn, Edward L

Volltext

Randomized Phase II Trial Designs With Biomarkers von FREIDLIN, Boris, MCSHANE, Lisa M, POLLEY, Mei-Yin C, KORN, Edward L

Volltext

Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials von RUBINSTEIN, Lawrence V, KORN, Edward L, FREIDLIN, Boris, HUNSBERGER, Sally, IVY, S. Percy, SMITH, Malcolm A

Volltext

Breast Cancer Classification and Prognosis Based on Gene Expression Profiles from a Population-Based Study von Sotiriou, Christos, Neo, Soek-Ying, McShane, Lisa M., Korn, Edward L., Long, Philip M., Jazaeri, Amir, Martiat, Philippe, Fox, Steve B., Harris, Adrian L., Liu, Edison T.

Volltext

Multi-Arm Clinical Trials of New Agents: Some Design Considerations von Freidlin, Boris, Korn, Edward L, Gray, Robert, Martin, Alison

Volltext

Design Issues in Randomized Phase II/III Trials von KORN, Edward L, FREIDLIN, Boris, ABRAMS, Jeffrey S, HALABI, Susan

Volltext

Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense? von DODD, Lori E, KORN, Edward L, FREIDLIN, Boris, JAFFE, C. Carl, RUBINSTEIN, Lawrence V, DANCEY, Janet, MOONEY, Margaret M

Volltext

Platform Trials — Beware the Noncomparable Control Group von Dodd, Lori E, Freidlin, Boris, Korn, Edward L

Volltext

Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements von Korn, Edward L, Freidlin, Boris

Volltext

Adaptive randomization versus interim monitoring von Freidlin, Boris, Korn, Edward L

Volltext

Augmenting randomized clinical trial data with historical control data: Precision medicine applications von Freidlin, Boris, Korn, Edward L

Volltext

Marker Sequential Test (MaST) design von Freidlin, Boris, Korn, Edward L, Gray, Robert

Volltext

Design of randomized clinical trials with a binary endpoint: Conditional versus unconditional analyses of a two‐by‐two table von Korn, Edward L., Freidlin, Boris

Volltext

Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007 von KORN, Edward L, FREIDLIN, Boris, MOONEY, Margaret, ABRAMS, Jeffrey S

Volltext

A Problematic Biomarker Trial Design von Freidlin, Boris, Korn, Edward L

Volltext

Dose optimization during drug development: whether and when to optimize von Korn, Edward L, Moscow, Jeffrey A, Freidlin, Boris

Volltext

Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005 von KORN, Edward L, FREIDLIN, Boris, MOONEY, Margaret

Volltext